Breakthrough T1D

“On april 14, 2016 jdrf amended and made significant changes to its bylaws. Changes that were made include provisions on formation and closing of chapters; and updated term limits of board members, officers, chancellors, and committee members. The bylaw amendments also redefine jdrf board committees and their responsibilities.”

“FORM 990, PART III, LINE 1 JDRFs mission is to accelerate life-changing breakthroughs to cure, prevent and treat Type 1 Diabetes (T1D) and its complications. JDRF is the leading global organization focused on T1D research and is committed to funding the development of new therapies and treatments to keep people with T1D healthier, longer, until a cure is found. Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF works every day to change the reality of this life-threatening autoimmune disease for millions of people - and to prevent anyone else from contracting the disease - by funding research, advocating for government support of research and new therapies, ensuring new therapies and technologies come to market, and connecting and engaging the T1D community. JDRF has funded more than $2 billion in research to date and made significant progress in understanding and fighting the disease. JDRF has played a role in nearly every T1D therapeutic advance of the past four decades, including the FDA-approved hybrid closed-loop artificial pancreas system in September 2016. PART III: STATEMENT OF PROGRAM SERVICE ACCOMPLISHMENTS LINE 4A ($75,084,432) RESEARCH FUNDING JDRF funds research with the greatest potential to cure, prevent and treat type 1 diabetes (T1D). Its strength lies in its exclusive focus and singular influence on the worldwide effort to end T1D. JDRF has committed more than $2 billion to this research since 1970. The full impact of JDRFs research investment extends well beyond direct funding. JDRF leverages partnerships with academia, industry and clinicians to ensure that the most promising research opportunities are funded and accelerated. JDRF often provides early stage funding to research projects, and the results of those projects often lead to follow-on participation from many other entities--both other non-for-profit funders and corporations. JDRF's research team is staffed by accomplished experts and leaders in the field of T1D science and medicine who guide the organization's funding efforts every step of the way. JDRFs highest priority remains funding research to deliver a cure for T1D and its complications. At the same time, JDRF is focused on developing better treatments that will transform the way people with T1D treat the disease today to help them live healthier lives now and in the future. The foundation's diversified research portfolio includes the following therapy areas: Artificial Pancreas: Artificial pancreas systems use technology to replicate the operation of a normal human pancreas and are one of the most revolutionary advances in diabetes care since the discovery of insulin. These systems link continuous glucose monitors and insulin pumps to smart software so that the right amount of insulin is delivered at the right time. Glucose Control: Glucose-responsive insulins(GRIs)--or smart insulins--promise to be a game-changer in blood-sugar management. GRIs will be the first-ever insulin formulation that turns on and off in response to blood sugar highs and lows. JDRF is also funding research that explores the benefits of combining novel or repurposed drugs with standard insulin therapy. Beta Cell Replacement: This therapy, also known as encapsulation, can be implanted to provide long-term relief from insulin dosing without the need for immune suppression. JDRF-supported scientists are improving biomaterials for encapsulation devices to protect implanted beta cells from autoimmune attack, among other strategies. Beta Cell Restoration: This drug or biologic-based therapy represents a full biological cure for people with T1D. It stimulates restoration of the bodys own beta cells and the capacity to produce insulin. We are repurposing drugs that may reduce beta cell stress and/or induce survival, as well as funding immune therapies that will stop the disease in its tracks. Complications: JDRF-funded research has already yielded new treatments for diabet”

“FORM 990- PART VI-SECT B, LINE 12C All officers, directors, key employees, board and committee members (both chapters and international boards) are required to sign a conflict of interest policy annually and disclose any conflicts. The Office of the President and CEO manages this process, and JDRF's internal audit department annually audits to ensure compliance. If any conflict does arise, the board members with the conflicts will recuse themselves from the meeting and/or vote.”

“FORM 990, PAGE 6, PART VI, SECTION C, LINE 19 The organization makes its governing documents, conflict of interest policy and financial statements available to the public on its website: www.JDRF.org. The public may access copies of JDRF's W-9, annual reports, 990 tax returns, 501(c)(3) IRS letter, and audited financials, at the following link: www.jdrf.org/about/financials”

“PART VI, SECTION B, LINES 15a & 15b JDRFs Board of Directors charges a Talent and Compensation Committee to develop and recommend a compensation philosophy that applies to all employees of JDRF, including recommendations regarding the compensation and benefits of JDRF senior management for approval by the Executive Committee. The Committee works in collaboration with the President and CEO and the Chief People Officer and other senior staff personnel in the JDRF Human Resources Department to ensure that 1) the Foundations talent strategy supports and is aligned with its overall organization strategies; 2) JDRF is in compliance with IRS guidelines for determining reasonableness in pay practices; and 3) overall compensation for JDRFs key executives is competitive and aligned with pay philosophy. To attract and retain top scientific and executive talent to advance its mission, the organization pays competitive and appropriate salaries as determined by analysis of reliable data and input from independent third-party consultants. The review of JDRF executive compensation and benefits under the procedures noted above is completed annually by the Compensation Committee, and the basis for their determination are documented contemporaneously in the minutes of the Committees meetings, including most recently on December 4, 2015.”

“SECTION B, PART VI, QUESTION 11B JDRF has a rigorous standard approach to reviewing its 990. The Organization's Tax Manager works with its outside tax professionals to prepare the return and all supporting schedules. The draft return is reviewed by a number of individuals, including JDRFs Chief Financial Officer and Director of Accounting and Finance, the Chief Executive Officer, other executives, its external senior tax advisor and others as necessary to ensure accuracy. Any questions and changes with respect to the draft return are addressed. Following this process, the return is reviewed by JDRFs Audit Committee of the Board of Directors with its outside tax advisors. Once approved, the return is distributed to all members of JDRFs Board of Directors for review and comment before it is filed with the Internal Revenue Service.”